Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Fulcrum Therapeutics Inc's Business Segments
Fulcrum Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Member
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | - | - |
Description of Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc. is a biotechnology company focused on developing therapeutics for rare genetic diseases. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.
Fulcrum Therapeutics is dedicated to addressing the underlying genetic causes of diseases by developing small molecule therapies that target specific genes. Their approach involves identifying and manipulating key regulatory interactions in the genome to restore normal gene expression and function.
The company's novel technology platform, known as the Control of Gene Expression (CoGE) platform, enables the identification of genes and pathways that are dysregulated in various rare genetic diseases. By understanding the mechanisms behind these diseases at a molecular level, Fulcrum aims to develop targeted therapies that can reverse the disease process.
Fulcrum Therapeutics has a diverse pipeline of drug candidates targeting different rare genetic diseases. These diseases include Fragile X syndrome, a genetic disorder that causes intellectual disability and behavioral abnormalities; Huntington's disease, a neurodegenerative disorder characterized by motor and cognitive impairments; and Facioscapulohumeral Muscular Dystrophy (FSHD), a progressive muscle wasting disease.
The CoGE platform enables Fulcrum to identify small molecules that can modulate gene expression, either by suppressing the expression of disease-causing genes or enhancing the expression of protective genes. These small molecules can potentially restore normal gene function and improve disease outcomes.
Fulcrum Therapeutics collaborates with academic institutions, research organizations, and patient advocacy groups to further enhance their understanding of disease biology and accelerate therapeutic development. They also utilize cutting-edge technologies, such as CRISPR gene editing and high-throughput screening, to identify and validate potential drug targets.
The company has a team of experienced scientists, clinicians, and drug development experts dedicated to advancing their pipeline and bringing innovative therapies to patients in need. They follow rigorous preclinical and clinical development processes to ensure the safety and efficacy of their drug candidates.
In summary, Fulcrum Therapeutics Inc. is a biotechnology company that focuses on developing small molecule therapies for rare genetic diseases. Their innovative CoGE platform enables the identification and manipulation of key regulatory interactions in the genome, with the aim of restoring normal gene expression and function. Through collaborations and cutting-edge technologies, Fulcrum strives to develop targeted therapies to improve the lives of patients with rare genetic diseases.
Fulcrum Therapeutics is dedicated to addressing the underlying genetic causes of diseases by developing small molecule therapies that target specific genes. Their approach involves identifying and manipulating key regulatory interactions in the genome to restore normal gene expression and function.
The company's novel technology platform, known as the Control of Gene Expression (CoGE) platform, enables the identification of genes and pathways that are dysregulated in various rare genetic diseases. By understanding the mechanisms behind these diseases at a molecular level, Fulcrum aims to develop targeted therapies that can reverse the disease process.
Fulcrum Therapeutics has a diverse pipeline of drug candidates targeting different rare genetic diseases. These diseases include Fragile X syndrome, a genetic disorder that causes intellectual disability and behavioral abnormalities; Huntington's disease, a neurodegenerative disorder characterized by motor and cognitive impairments; and Facioscapulohumeral Muscular Dystrophy (FSHD), a progressive muscle wasting disease.
The CoGE platform enables Fulcrum to identify small molecules that can modulate gene expression, either by suppressing the expression of disease-causing genes or enhancing the expression of protective genes. These small molecules can potentially restore normal gene function and improve disease outcomes.
Fulcrum Therapeutics collaborates with academic institutions, research organizations, and patient advocacy groups to further enhance their understanding of disease biology and accelerate therapeutic development. They also utilize cutting-edge technologies, such as CRISPR gene editing and high-throughput screening, to identify and validate potential drug targets.
The company has a team of experienced scientists, clinicians, and drug development experts dedicated to advancing their pipeline and bringing innovative therapies to patients in need. They follow rigorous preclinical and clinical development processes to ensure the safety and efficacy of their drug candidates.
In summary, Fulcrum Therapeutics Inc. is a biotechnology company that focuses on developing small molecule therapies for rare genetic diseases. Their innovative CoGE platform enables the identification and manipulation of key regulatory interactions in the genome, with the aim of restoring normal gene expression and function. Through collaborations and cutting-edge technologies, Fulcrum strives to develop targeted therapies to improve the lives of patients with rare genetic diseases.
Fulcrum Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat rare and devastating diseases with significant unmet medical need. The companys primary focus is on diseases caused by genetic mutations or specific molecular pathways, particularly in the realm of muscle disorders. Below is an extensive description of the segments, products, and services that Fulcrum Therapeutics may offer.
Segments
1. Rare Disease Segment:
- This segment focuses on developing treatments for rare genetic disorders, often involving significant morbidity and mortality. Fulcrum targets specific populations affected by neuromuscular diseases, among other conditions.
2. Duchenne Muscular Dystrophy (DMD) Segment:
- DMD is a key area of interest for Fulcrum Therapeutics. The company is involved in creating therapies that aim to modify the disease progression and improve quality of life for patients.
3. Genetic Medicine:
- This segment encompasses therapies designed to address genetic mutations directly, including the use of gene editing technologies and RNA-targeted approaches.
Products
1. Fulfirin (also known as FK-101):
- Fulcrums lead candidate aimed primarily at treating DMD by modulating the expression of genes involved in the diseases pathology. This product is designed to increase the levels of dystrophin, a protein essential for muscle function, thereby alleviating some symptoms of the disease.
2. Research and Development Pipeline:
- Fulcrum may have multiple candidates in various stages of preclinical and clinical development. This pipeline often includes:
- Phase 1/Phase 2 Trials: Testing safety, dosage, and initial efficacy in small patient populations.
- Preclinical Studies: Research involving laboratory or animal studies to assess potential efficacy and safety before moving to human trials.
3. Collaborative Programs:
- Fulcrum often engages in collaborative agreements with academic institutions and other biotech firms to jointly develop therapeutic candidates. These partnerships may focus on shared interests in specific genetic disorders or innovative treatment modalities.
Services
1. Clinical Trial Services:
- Fulcrum Therapeutics may offer comprehensive clinical trial services, including study design, patient recruitment, clinical monitoring, and regulatory compliance. Through these services, they ensure that clinical trials run smoothly and yield data that meet regulatory standards.
2. Patient Advocacy and Support Services:
- The company likely engages in outreach to support patients and families affected by the diseases they aim to treat. This may include educational resources, connecting with advocacy groups, and enhancing access to treatment solutions.
3. Consultative Services:
- Fulcrum may provide consultative services to other biotech companies and research institutions, leveraging its expertise in drug development, genetic disorders, and regulatory pathways.
4. Data Analysis and Insights:
- Utilizing advanced data analytics, Fulcrum may offer insights into disease progression and treatment outcomes, contributing to the broader understanding of muscular dystrophies and other rare diseases.
Innovative Approaches
Fulcrum Therapeutics is known for its innovative approach to drug development, often utilizing proprietary drug discovery platforms. This may include assessing genetic factors that contribute to disease pathology and seeking targeted therapies that address these specific molecular causes.
Summary
Fulcrum Therapeutics is positioned at the intersection of cutting-edge science and patient need, focusing on rare genetic diseases, with an emphasis on muscular disorders. Its diverse range of products and services is geared toward the discovery and development of effective therapeutic strategies while actively engaging with the patient community to ensure their needs are adequately addressed in the evolving landscape of rare disease treatment.
Segments
1. Rare Disease Segment:
- This segment focuses on developing treatments for rare genetic disorders, often involving significant morbidity and mortality. Fulcrum targets specific populations affected by neuromuscular diseases, among other conditions.
2. Duchenne Muscular Dystrophy (DMD) Segment:
- DMD is a key area of interest for Fulcrum Therapeutics. The company is involved in creating therapies that aim to modify the disease progression and improve quality of life for patients.
3. Genetic Medicine:
- This segment encompasses therapies designed to address genetic mutations directly, including the use of gene editing technologies and RNA-targeted approaches.
Products
1. Fulfirin (also known as FK-101):
- Fulcrums lead candidate aimed primarily at treating DMD by modulating the expression of genes involved in the diseases pathology. This product is designed to increase the levels of dystrophin, a protein essential for muscle function, thereby alleviating some symptoms of the disease.
2. Research and Development Pipeline:
- Fulcrum may have multiple candidates in various stages of preclinical and clinical development. This pipeline often includes:
- Phase 1/Phase 2 Trials: Testing safety, dosage, and initial efficacy in small patient populations.
- Preclinical Studies: Research involving laboratory or animal studies to assess potential efficacy and safety before moving to human trials.
3. Collaborative Programs:
- Fulcrum often engages in collaborative agreements with academic institutions and other biotech firms to jointly develop therapeutic candidates. These partnerships may focus on shared interests in specific genetic disorders or innovative treatment modalities.
Services
1. Clinical Trial Services:
- Fulcrum Therapeutics may offer comprehensive clinical trial services, including study design, patient recruitment, clinical monitoring, and regulatory compliance. Through these services, they ensure that clinical trials run smoothly and yield data that meet regulatory standards.
2. Patient Advocacy and Support Services:
- The company likely engages in outreach to support patients and families affected by the diseases they aim to treat. This may include educational resources, connecting with advocacy groups, and enhancing access to treatment solutions.
3. Consultative Services:
- Fulcrum may provide consultative services to other biotech companies and research institutions, leveraging its expertise in drug development, genetic disorders, and regulatory pathways.
4. Data Analysis and Insights:
- Utilizing advanced data analytics, Fulcrum may offer insights into disease progression and treatment outcomes, contributing to the broader understanding of muscular dystrophies and other rare diseases.
Innovative Approaches
Fulcrum Therapeutics is known for its innovative approach to drug development, often utilizing proprietary drug discovery platforms. This may include assessing genetic factors that contribute to disease pathology and seeking targeted therapies that address these specific molecular causes.
Summary
Fulcrum Therapeutics is positioned at the intersection of cutting-edge science and patient need, focusing on rare genetic diseases, with an emphasis on muscular disorders. Its diverse range of products and services is geared toward the discovery and development of effective therapeutic strategies while actively engaging with the patient community to ensure their needs are adequately addressed in the evolving landscape of rare disease treatment.